C4X Discovery Holdings PLC Director/PDMR Shareholding (1970L)
17 April 2018 - 9:50PM
UK Regulatory
TIDMC4XD
RNS Number : 1970L
C4X Discovery Holdings PLC
17 April 2018
This announcement contains inside information
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
PDMR Shareholdings
17 April 2018 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering drug discovery company, announces that Dr Clive Dix,
Chief Executive Officer, has today purchased 70,000 ordinary shares
of 1 pence each in the Company ("Ordinary Shares"), of which 10,000
Ordinary Shares were purchased at a price of 108.5 pence per
Ordinary Share and 60,000 Ordinary Shares were purchased at a price
of 113.0 pence per Ordinary Share (the "Dealing"). Following the
Dealing, Dr Clive Dix holds 1,414,936 Ordinary Shares, which
represents an interest in 3.04% of the Company's issued share
capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and/or persons closely
associated with them:
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr Clive Dix
------------------------------------------------------------ ------------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------------------------------
Chief Executive Officer, Director
a) Position/status
------------------------------------------------------------ ------------------------------------------
b) Initial notification/Amendment Initial Notification
------------------------------------------------------------ ------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
--------------------------------------------------------------------------------------------------------
a) Name C4X Discovery Holdings plc
------------------------------------------------------------ ------------------------------------------
b) LEI N/A
------------------------------------------------------------ ------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
--------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of instrument 1p ordinary shares
Identification code
ISIN GB00BQQ2RV18
------------------------------------------------------------ ------------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares
------------------------------------------------------------ ------------------------------------------
c) Price(s) and volume(s) Price(s) per Ordinary Share Volume(s)
108.5 10,000
113.0 60,000
----------
------------------------------------------------------------ ------------------------------------------
d) Aggregated information Price Volume(s)
GBP78,650 70,000
----------
------------------------------------------------------------ ------------------------------------------
e) Date of the transaction 17 April 2018
------------------------------------------------------------ ------------------------------------------
f) Place of the transaction London Stock Exchange - AIM
------------------------------------------------------------ ------------------------------------------
Name of authorised official of issuer responsible for making
notification: Brad Hoy, Chief Financial Officer of the Company.
--ENDS-
For further information, please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer 07801 865 803
Panmure Gordon (UK) Limited (NOMAD and Broker) 020 7886 2500
Freddy Crossley, Emma Earl (Corporate Finance)
Tom Salvesen (Corporate Broking)
Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal 0203 709 5700
About C4X Discovery
C4X Discovery aims to become the world's most productive drug
discovery engine by exploiting cutting edge technologies to design
and create best-in-class small-molecule candidates targeting a
range of high value therapeutic areas. The company's goal is to
drive returns through early-stage revenue-generating deals with the
pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary
technologies across the drug discovery process. The company's
innovative DNA-based target identification platform (Taxonomy3(R))
utilises human genetic datasets to identify novel patient-specific
targets leading to greater discovery productivity and increased
probability of clinical success. This is complemented by C4XD's
novel drug design platform which comprises two innovative chemistry
technologies, Conformetrix and Molplex, that combine 4D molecular
shape analyses (based on experimental data) with best-in-class
computational chemistry. This provides new and unprecedented
insight into the behaviour of drug molecules, enabling the
production of potent selective compounds faster and more cost
effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline in
inflammation, neurodegeneration, immuno-oncology, addiction, and
diabetes with a number of new drug candidates identified and
further progress made towards the pre-clinical licensing
discussions. In selecting new targets C4X Discovery will focus on
the high-value disease areas and will continue to maximise value
from opportunistic areas, for example, immuno-oncology, addiction,
and diabetes.
The Company was founded as a spin-out from the University of
Manchester. It has a highly experienced management team and Board
who have delivered significant value creation within the healthcare
sector historically and have enabled C4XD to reach multiple value
inflexion points since IPO. For additional information please go
to: www.c4xdiscovery.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEAFLXFLXPEFF
(END) Dow Jones Newswires
April 17, 2018 07:50 ET (11:50 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024